MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that management will present an overview of the company's business, including certain preliminary 2015 results and 2016 outlook, at the 34th Annual J.P. Morgan Healthcare Conference.
Intersect ENT’s presentation will take place on Tuesday, January 12, 2016 at 1:30 p.m. PT at the Westin St. Francis Hotel in San Francisco.
A live webcast of the presentation will be available online from the Investor Relations page of the company's website at http://www.intersectENT.com. The webcast replay will be available for approximately one month.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL® and PROPEL® mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
For additional information on the company or the products including risks and benefits please visit www.intersectENT.com.
XENT-F
